Title:
PHARMACEUTICAL PREPARATION CONTAINING PYRIDYL AMINOACETIC ACID COMPOUND
Document Type and Number:
WIPO Patent Application WO/2019/131901
Kind Code:
A1
Abstract:
The purpose of the present invention is to discover a pharmaceutical preparation which is for treating or preventing glaucoma or intraocular hypertension and exhibits effects on a patient in which the efficacy of a therapeutic agent for glaucoma or intraocular hypertension is insufficient. It is found that omidenepag, an ester thereof, or a salt thereof is proven to exhibit an excellent intraocular tension depressive action on a patient in which the efficacies of other therapeutic agents for glaucoma or intraocular hypertension are insufficient. Therefore, omidenepag, an ester thereof, or a salt thereof according to the present invention is useful as a pharmaceutical preparation capable of treating or preventing glaucoma or intraocular hypertension even on a patient in which the efficacies of other therapeutic agents for glaucoma or intraocular hypertension are insufficient.
Inventors:
KAWATA HISASHI (JP)
KAWABATA NORIKO (JP)
SHAMS NAVEED (US)
KAWABATA NORIKO (JP)
SHAMS NAVEED (US)
Application Number:
PCT/JP2018/048228
Publication Date:
July 04, 2019
Filing Date:
December 27, 2018
Export Citation:
Assignee:
SANTEN PHARMACEUTICAL CO LTD (JP)
International Classes:
A61K31/444; A61K31/5575; A61P27/06
Domestic Patent References:
| WO2017006985A1 | 2017-01-12 | |||
| WO2015105144A1 | 2015-07-16 | |||
| WO2017006985A1 | 2017-01-12 | |||
| WO2017002941A1 | 2017-01-05 |
Foreign References:
| US20120190852A1 | 2012-07-26 | |||
| US20110054172A1 | 2011-03-03 | |||
| US20140018396A1 | 2014-01-16 | |||
| US20140018350A1 | 2014-01-16 | |||
| US20150196541A1 | 2015-07-16 | |||
| US20160317512A1 | 2016-11-03 | |||
| US20160317664A1 | 2016-11-03 |
Other References:
ODANI, NORIKO: "Development of intraocular pressure lowering drugs of a new action mechanism - Selective EP 2 receptor agonists, Omidenepag Isopropyl ophthalmic solution", PROGRAMS AND LECTURE ABSTRACTS OF THE 37TH ANNUAL SCIENTIFIC MEETING OF THE JAPANESE SOCIETY FOR OCULAR PHARMACOLOGY, XP055289484
KALOUCHE, G. ET AL.: "Activation of Prostaglandin FP and EP 2 Receptors Differently Modulates Myofibroblast Transition in a Model of Adult Primary Human Trabecular Meshwork Cells", INVEST OPHTHALMOL VIS SCI, vol. 57, no. 4, 2016, pages 1816 - 1825, XP055624516, ISSN: 0146-0404
AIHARA, MAKOTO ET AL.: "The Intraocular pressure lowering effect of tafluprost in latanoprost hyporesponsive monkeys", JOURNAL OF JAPANESE OPHTHALMOLOGICAL SOCIETY, vol. 113, no. 01-017, pages 195, ISSN: 0029-0203
KOCULUK, Y. ET AL.: "Efficacy of Monotherapy with Either Bimatoprost or Travoprost in Patients with Primary Open-Angle Glaucoma Resistant to Latanoprost Therapy", TURK J OPHTHALMOL, vol. 41, no. 5, 2011, pages 295 - 298, XP055624519, ISSN: 1300-0659
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 1187451-19-9
KALOUCHE, G. ET AL.: "Activation of Prostaglandin FP and EP 2 Receptors Differently Modulates Myofibroblast Transition in a Model of Adult Primary Human Trabecular Meshwork Cells", INVEST OPHTHALMOL VIS SCI, vol. 57, no. 4, 2016, pages 1816 - 1825, XP055624516, ISSN: 0146-0404
AIHARA, MAKOTO ET AL.: "The Intraocular pressure lowering effect of tafluprost in latanoprost hyporesponsive monkeys", JOURNAL OF JAPANESE OPHTHALMOLOGICAL SOCIETY, vol. 113, no. 01-017, pages 195, ISSN: 0029-0203
KOCULUK, Y. ET AL.: "Efficacy of Monotherapy with Either Bimatoprost or Travoprost in Patients with Primary Open-Angle Glaucoma Resistant to Latanoprost Therapy", TURK J OPHTHALMOL, vol. 41, no. 5, 2011, pages 295 - 298, XP055624519, ISSN: 1300-0659
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 1187451-19-9
Attorney, Agent or Firm:
TANAKA Shinichiro et al. (JP)
Download PDF:
Previous Patent: GRAVURE PRINTING METHOD
Next Patent: THERAPEUTIC AGENT FOR STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE
Next Patent: THERAPEUTIC AGENT FOR STRESS URINARY INCONTINENCE AND FECAL INCONTINENCE